Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 25, Issue 5, 2011, Pages 617-629

  Almonte, Maribel ^a   Sasieni, Peter ^a   Cuzick, Jack ^a   Snow, John ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervical screening; Cytology; High risk HPV; HPV 16 18; HPV testing; Prophylactic vaccines

Indexed keywords

WART VIRUS VACCINE; VIRUS DNA;

ARTICLE; CANCER IMMUNIZATION; CANCER SCREENING; CYTODIAGNOSIS; DEVELOPED COUNTRY; DIAGNOSTIC TEST; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; PAPILLOMAVIRUS INFECTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RELIABILITY; UTERINE CERVIX CANCER; VIRUS CULTURE; VIRUS DETECTION; WART VIRUS; AGE; ALPHAPAPILLOMAVIRUS; DEVELOPING COUNTRY; EARLY DIAGNOSIS; FEMALE; GENETICS; ISOLATION AND PURIFICATION; REVIEW; UTERINE CERVIX TUMOR; VAGINA SMEAR;

AGE FACTORS; ALPHAPAPILLOMAVIRUS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 80455159098     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2011.05.003     Document Type: Review

References (58)

1. Ferlay J, Shin H, Bray F et al. GLOBOCAN 2008. Cancer incidence and mortality worldwide. IARC CancerBase No. 10 2010.
2. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19. (Pubitemid 29406813)
3. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868. (Pubitemid 46829356)
4. Cuzick J, Arbyn M, Sankaranarayanan R et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26(Suppl. 10): K29-41.
5. Papanicolaou GN. New cancer diagnosis. Paper presented at: Proceedings of the third race betterment conference 1928; Battle Creek, Michigan.
6. Babes A. Diagnostic du cancer du col uterin par les frottis. Presse Med. 1928; 36: 451-454.
7. Papanicolaou GN & Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941; 42: 193-206.
8. Sasieni P & Adams J. Effect of screening on cervical cancer mortality in England and Wales: analysis of trends with an age period cohort model. Bmj 1999; 318: 1244-1245. (Pubitemid 29210053)
9. van der Aa MA, Pukkala E, Coebergh JW et al. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer 2008; 122: 1854-1858. (Pubitemid 351413434)
10. Sasieni PD, Cuzick J & Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The national Co-ordinating network for cervical screening working group. Br J Cancer 1996; 73: 1001-1005. (Pubitemid 26116757)
11. Peto J, Gilham C, Fletcher O et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249-256. (Pubitemid 38942814)
12. Gustafsson L, Ponten J, Zack M et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8: 755-763. (Pubitemid 27404646)
13. Wang SS, Sherman ME, Hildesheim A et al. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004; 100: 1035-1044. (Pubitemid 38232621)
14. Arbyn M, Bergeron C, Klinkhamer P et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol. 2008; 111: 167-177.
15. Lorincz A. Detection of human papillomavirus DNA without amplification: prospects for clinical utility. IARC Sci Publ 1992: 135-145.
16. Castle PE, Fetterman B, Poitras N et al. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009; 113: 595-600.
17. NHS cervical screening programme. Annual review. Available at: 2010 http://www.cancerscreening.nhs.uk/cervical/publications/2010review.html.
18. Almonte M, Murillo R, Sanchez GI et al. New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud Publica De Mexico 2010; 52: 544-559.
19. Smith RA, Cokkinides V, von Eschenbach AC et al. American cancer society guidelines for the early detection of cancer. CA Cancer J Clin 2002; 52: 8-22. (Pubitemid 34110468)
20. ACOG practice bulletin. Cervical cytology screening. Number 45, August 2003. Int J Gynaecol Obstet 2003; 83: 237-247.
21. ACOG Practice Bulletin no. 109. Cervical cytology screening. Obstet Gynecol 2009; 114: 1409-1420.
22. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101. (Pubitemid 44116919)
23. Zhao FH, Lin MJ, Chen F et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol 2010; 11: 1160-1171.
24. Luyten A, Scherbring S, Reinecke-Luthge A et al. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany-experience over 3 years. J Clin Virol 2009; 46(Suppl. 3): S5-10.
25. Gravitt PE, Paul P, Katki HA et al. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India. PLoS One 2010; 5: e13711.
26. Lazcano-Ponce E, Lorincz AT, Salmeron J et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control 2010; 21: 1693-1700.
27. Wu R, Belinson SE, Du H et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen cervical cancer screening trial I. Int J Gynecol Cancer 2010; 20: 1411-1414.
28. McAdam M, Sakita J, Tarivonda L et al. Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS One 2010; 5: e13266.
29. ® 4800 HPV 16/18 positive women ≥30 years with NILM cytology: ATHENA results. Paper presented at:. In: 26th International Papillomavirus Conference; July 3-11, 2010 2010. Montreal, Canada.
30. Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597. (Pubitemid 47598401)
31. Bulkmans NW, Rozendaal L, Snijders PJ et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004; 110: 94-101. (Pubitemid 38507208)
32. Kitchener HC, Almonte M, Wheeler P et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 2006; 95: 56-61. (Pubitemid 43980554)
33. Ronco G, Segnan N, Giorgi-Rossi P et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006; 98: 765-774. (Pubitemid 43983300)
34. Ronco G, Giorgi-Rossi P, Carozzi F et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501.
35. Kotaniemi-Talonen L, Nieminen P, Anttila A et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005; 93: 862-867. (Pubitemid 41487010)
36. Sankaranarayanan R, Nene BM, Dinshaw KA et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 2005; 116: 617-623. (Pubitemid 41099199)
37. Ogilvie GS, van Niekerk DJ, Krajden M et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 2010; 10: 111.
38. Monsonego J, Hudgens MG, Zerat L et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquidbased cytology in primary cervical cancer screening: The FASE study. Int J Cancer 2011; 129: 691-701.
39. Cuzick J, Ambroisine L, Cadman L et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010; 82: 1186-1191.
40. Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008; 17: 3033-3042.
41. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-1079. (Pubitemid 41417924)
42. Kjaer SK, van den Brule AJ, Paull G et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 572.
43. Cuzick J, Szarewski A, Mesher D et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from the Hammersmith study. Int J Cancer 2008; 122: 2294-2300. (Pubitemid 351542334)
44. Clavel C, Masure M, Bory JP et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 84: 1616-1623. (Pubitemid 32612492)
45. Elfgren K, Rylander E, Radberg T et al. Colposcopic and histopathologic evaluation of women participating in populationbased screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005; 193: 650-657. (Pubitemid 41261457)
46. de Sanjose S, Almirall R, Lloveras B et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003; 30: 788-793. (Pubitemid 37229490)
47. Petry KU, Menton S, Menton M et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570-1577. (Pubitemid 36713784)
48. Dillner J, Rebolj M, Birembaut P et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
49. Sasieni P, Castanon A & Parkin DM. How many cervical cancers are prevented by treatment of screen-detected disease in young women? Int J Cancer 2009; 124: 461-464.
50. Sasieni P, Castanon A & Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968.
51. Cuzick J, Castanon A & Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102: 933-939.
52. Murillo R, Almonte M, Pereira A et al. Cervical cancer screening programs in Latin America and the Caribbean. Vaccine 2008; 26(Suppl. 11): L37-48.
53. Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a crosssectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-936.
54. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.
55. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765. (Pubitemid 39488060)
56. Garnett GP, Kim JJ, French K et al. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006; 24(Suppl. 3): S3.178-S3.186.
57. Franceschi S, Denny L, Irwin KL et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011; 128: 2765-2774.
58. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191(Suppl. 1): S97-106. (Pubitemid 40144234)